

Coronary artery calcification is associated with alcohol intake but not oxidative stress or inflammation

NATALIE C WARD, KEVIN D CROFT, HENRIETTA HEADLAM, TREVOR A MORI, KEITH WOOLLARD, IAN B PUDDEY

Abstract

Coronary artery calcification (CAC) is a component of the development of atherosclerosis. Coronary computed tomography scanning (CCT) can detect calcification and may be useful in individuals considered asymptomatic. Oxidative stress and inflammation are linked through common pathways and both are thought to be involved in the pathogenesis of atherosclerosis. To investigate if CAC was associated with increased oxidative stress (plasma F₂-isoprostanes) and inflammation (high sensitivity C-reactive protein [hs-CRP]), we invited 102 self-selected individuals (mean age 52±7 years) who were undergoing CCT to take part in a study. Height, weight and clinic blood pressure was measured, a blood sample taken and a health and lifestyle questionnaire completed.

CAC was found to be positively correlated with age ($p<0.01$) and alcohol intake ($p<0.001$). There was a trend for higher CAC in men compared to women ($p=0.08$). CAC was higher in ex- and current smokers versus non-smokers (115±45 vs. 28±12 Agatston score, $p=0.05$), and lower in non-drinkers versus drinkers (18±17 vs. 90±29 Agatston score, $p=0.03$). There were no univariate correlations between CAC and plasma F₂-isoprostanes ($p=0.25$) or HS-CRP ($p=0.36$). In multivariate analysis, age, male gender and alcohol intake remained independent predictors of CAC. We

concluded that CAC was not associated with inflammation or oxidative stress, but was related to lifestyle factors including; age, gender and alcohol consumption.

Key words. coronary artery calcification, oxidative stress, inflammation, alcohol.

Br J Cardiol 2007; **14**:37–40

Introduction

Coronary artery disease (CAD) is a leading cause of morbidity and mortality¹ and the process of coronary artery calcification (CAC) contributes to the development of atherosclerosis.² Coronary computed tomography scanning (CCT) is a sensitive technique for detecting CAC. It may be used for screening high-risk asymptomatic people and for the diagnosis of obstructive CAD. CCT quantitates the extent of calcium detected as a 'mass' or 'score'. Scores correlate with angiographically significant disease and are regarded as a marker of atherosclerotic plaque burden.²

Oxidative damage to low-density lipoproteins is thought to be involved in the pathogenesis of atherosclerosis.³ Atherosclerosis has also been described as an inflammatory disease process.⁴ Soft tissue calcification has been observed in areas of chronic inflammation and atherosclerotic calcification may be a process where oxidised lipids are involved in the inflammatory process.⁵

Since the involvement of oxidative stress in early lesion development is still uncertain, the objective of the study was to investigate the relationship between CAC and oxidative stress (plasma F₂-isoprostanes) and inflammation (high-sensitivity C-reactive protein [hs-CRP]).

Methods

Participants

Patients attending Western Australia Cardiology Services to undergo a coronary CT scan were invited into the study. Individuals completed a health and lifestyle questionnaire detailing medication use, physical activity and alcohol intake; they had their height, weight and clinic blood pressure (BP) measured; and they provided a non-fasting blood sample. The study was

School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Box X2213 GPO, Perth, WA 6847, Australia.

Natalie C Ward, Research Fellow

Kevin D Croft, Associate Professor of Medicine

Henrietta Headlam, Research Fellow

Trevor A Mori, Senior Lecturer

Ian B Puddey, Dean of Faculty of Medicine, Dentistry & Health Sciences

Fremantle Hospital and Western Australia Cardiology Services, Suite 34, 100 Murdoch Drive, Murdoch, WA 6150, Australia.

Keith Woollard, Cardiologist

Correspondence to: Dr N C Ward

(E-mail: nward@meddent.uwa.edu.au)

Table 1. Patient characteristics

	Total	Men	Women	p value
Number	102	73	29	
Age (years)	52.8±0.7	52.5±0.9	53.6±1.4	0.520
BMI (kg/m ²)	27.05±0.5	28.1±0.6	25.9±0.7	0.034
Systolic BP (mmHg)	129±1.4	130±1.7	126±2.5	0.125
Diastolic BP (mmHg)	80.5±0.8	81.8±0.9	77.2±1.4	0.006
Cholesterol (mmol/L)	5.83±0.12	5.87±0.14	5.75±0.2	0.654
Triglycerides (mmol/L)	2.21±0.15	2.32±0.16	1.94±0.31	0.239
HDL (mmol/L)	1.34±0.07	1.26±0.10	1.55±0.08	0.071
Glucose (mmol/L)	5.5±0.2	5.6±0.2	5.5±0.2	0.491
Alcohol intake (g/wk)	143±18	181±24	46±10	<0.0001
History of hypertension*	36%	41%	25%	0.153
- on 1 drug	10%	11%	7%	
- on 2 drugs	6%	6%	7%	
History of dyslipidaemia*	50%	53%	43%	0.373
- on statins	17%	19%	14%	
- on fibrates	1%		3%	
Type on 2 diabetes	4%	3%	7%	0.317
HRT	12/29		41%	
Gout	4%	4%	4%	0.203
Aspirin	11%	11%	11%	0.955
Antioxidants/vitamins	37%	31%	54%	0.032
Current/ex-/non-smokers	14/43/43%	17/53/30%	4/18/78%	<0.0001
Non-drinkers/drinkers	18/82%	12/88%	32/68%	0.025
Agatston score				<0.0001
0	45%	32%	79%	
< 100	36%	45%	14%	
> 100	15%	18%	7%	

Mean ± SEM, Independent samples t-test

Key: BMI = body mass index; BP = blood pressure; HDL = high-density lipoproteins; HRT = hormone replacement therapy; *hypertension and dyslipidaemia were defined as previous diagnosis by clinician or use of antihypertension or lipid-lowering therapy, respectively



approved by the Fremantle Hospital and Health Services Human Research Ethics Committee. A written informed consent was obtained before inclusion in the study.

Coronary computed tomography scanning

Coronary computed tomography scanning (CCT) studies were performed on a Toshiba AQUILION CT Scanner. Helical studies were performed from the root of the aorta to the cardiac apex at 3 mm slices and 0.3 seconds per slice, utilising 3–4 breath holds. CAC was grouped in pre-selected categories; 0 Agatston score, 1–100 Agatston score and > 100 Agatston score, as previously described.⁶

Biochemistry

Plasma F₂-isoprostane concentrations were analysed using gas-chromatography mass spectrometry.⁷ Serum hs-CRP was analysed via particle-enhanced immunonephelometry. Lipids and glucose were measured using an automated analyser.

Figure 1. Coronary artery calcium and smoking. Pearson Chi-square 17.8, p<0.001**Figure 2.** Plasma F₂-isoprostanes and smoking. ANOVA, p=0.378

Statistical analysis

Statistical analysis was carried out using the Statistical Package for Social Sciences. Non-normally distributed data was log-transformed prior to analysis and results presented as mean ± SEM or geometric mean (95% confidence intervals). Independent samples t-tests were used to determine gender differences. Pearson Chi-squared and ANOVA with Bonferroni post-hoc comparisons were used to determine relationships between CAC and oxidative stress, inflammation, smoking and alcohol intake. Logistical regression was used to determine predictors of CAC.

Results

Seventy-three men and 29 women took part in the study. Men had significantly higher body mass index (BMI), diastolic BP and alcohol intake, and were more likely to be smokers, ex-smokers and drinkers. Women were higher consumers of antioxidant or vitamin supplements (table 1). Over 50% of the whole group had detectable calcification, although this was significantly more pronounced in men (table 1).

Calcification was significantly higher in current or ex-smokers (figure 1). Plasma F₂-isoprostane concentrations tended to be

Figure 3. Coronary artery calcium and alcohol intake. Pearson Chi-square 17.5, $p=0.008$





Figure 4. Plasma F₂-isoprostanes and alcohol intake. ANOVA, $p=0.785$



higher in current or ex-smokers (figure 2). Individuals who consumed one or more standard alcoholic drinks per day (> 70 g/week) had more CAC (figure 3), but there was no difference for plasma F₂-isoprostanes (figure 4). Plasma F₂-isoprostane concentrations were not different between tertiles of CAC (1,101 [992, 1,212] vs. 1,041 [863, 1,528] vs. 1,022 [829, 1,248] pmol/L for an Agatston score of 0, 1–100 or > 100 , respectively, $p=0.779$). The hs-CRP was not significantly different between tertiles of CAC (1.78 [1.27, 2.48] vs. 1.78 [1.27, 2.49] vs. 1.56 [1.22, 2.70] mg/L for an Agatston score of 0, 1–100, > 100 , respectively, $p=0.908$).

Independent predictors of CAC were age ($B=0.098$, $p=0.014$), male gender ($B=2.139$, $p=0.003$) and alcohol intake ($B=2.428$, $p=0.021$). Neither hs-CRP nor plasma F-isoprostanes predicted CAC.

Discussion

This study has shown positive associations of CAC with age, male gender and alcohol intake, and greater CAC prevalence in smokers. There was no association between CAC and oxidative stress or inflammation.

Our data support a recent study which observed a direct association between high alcohol intake and coronary calcifica-



Key messages

- Coronary artery calcification was not related to oxidative stress or inflammation in this self-selected population
- Lifestyle factors such as age, male gender and alcohol consumption were independent predictors of coronary artery calcification

tion in young, healthy asymptomatic individuals.⁸ Our present study included middle-aged individuals with existing cardiovascular disease. Taken together, these results may highlight an association between increasing alcohol intake and CAC in individuals of all ages and disease states. Although men consumed more alcohol than women, our association remained significant after adjustment for age and gender.

Low plasma ascorbic acid⁹ and increased plasma F₂-isoprostanes¹⁰ are associated with CAC. However, we saw no association between plasma F₂-isoprostanes and CAC. Previous studies included young, healthy individuals^{9,10} while our study included older participants; several had pre-existing cardiovascular risk factors. Furthermore, over 50% of our subjects had detectable CAC, suggesting the present population had a greater prevalence and possibly more advanced atherosclerosis. It may be that oxidative stress predicts the development of CAC at an early stage but the relationship is lost in an older population with existing cardiovascular disease risk factors.

Another significant difference is that lipid peroxidation was previously assessed by measurement of free plasma F₂-isoprostanes¹⁰ while we examined total plasma isoprostanes (sum of free and phospholipid-bound isoprostanes). Free plasma isoprostane levels may be a result of increased phospholipase A₂ (PLA₂) activity, which hydrolyses phospholipids. Thus, the previous association¹⁰ may actually reflect an association between PLA₂ and CAC. A positive association between lipoprotein-associated phospholipase A₂ and risk of heart disease has been described.¹¹

Additional factors contributing to these differences may include large heterogeneity within the population, use of a self-selected population, self-reported medical history and relatively small group sizes, particularly in relation to women. However, this heterogeneity is reflective of the general population.

The positive associations we observed between CAC and age and male gender are not unexpected. We also observed higher prevalence of CAC in current or ex-smokers and drinkers. Although smoking^{12,13} and alcohol intake^{14,15} are important sources of oxidative stress, this does not appear to explain the link with CAC. We did not show any association between CAC and inflammation, which is supported by a previous study.¹⁶

In conclusion, the present study has shown that CAC score is not related to oxidative stress or inflammation in this population. Age, male gender and alcohol intake were positively associated with CAC, consistent with the involvement of lifestyle factors in CVD.

Acknowledgements

We thank Dayalan Vignarajan (posthumous), the nursing staff at Western Australia Cardiology Services for their assistance, and the volunteers who took part in the study.

Conflict of interest

This study was supported by a Fremantle Hospital Medical Research Foundation Grant, Australia.

References

1. Rich S, McLaughlin VV. Detection of subclinical cardiovascular disease: the emerging role of electron beam computed tomography. *Prev Med* 2002;**34**:1-10.
2. O'Rourke RA, Brundage BH, Froelicher VF *et al*. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. *Circulation* 2000;**102**:126-40.
3. Witztum JL. The oxidation hypothesis of atherosclerosis. *Lancet* 1994;**344**:793-5.
4. Ross R. Atherosclerosis - an inflammatory disease. *N Engl J Med* 1999;**340**:115-26.
5. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. *Arterioscler Thromb Vasc Biol* 2004;**24**:1161-70.
6. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. *JAMA* 2004;**291**:210-15.
7. Mori TA, Croft KD, Puddey IB, Beilin LJ. An improved method for the measurement of urinary and plasma F2- isoprostanes using gas chromatography-mass spectrometry. *Anal Biochem* 1999;**268**:117-25.
8. Pletcher MJ, Varosy P, Kiefe CI, Lewis CE, Sidney S, Hulley SB. Alcohol consumption, binge drinking, and early coronary calcification: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. *Am J Epidemiol* 2005;**161**:423-33.
9. Simon JA, Murtaugh MA, Gross MD, Loria CM, Hulley SB, Jacobs DR, Jr. Relation of ascorbic acid to coronary artery calcium: the Coronary Artery Risk Development in Young Adults Study. *Am J Epidemiol* 2004;**159**:581-8.
10. Gross M, Steffes M, Jacobs DR, Jr *et al*. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. *Clin Chem* 2005;**51**:125-31.
11. Packard CJ, O'Reilly DS, Caslake MJ *et al*. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 2000;**343**:1148-55.
12. Kaufmann PA, Gnechchi-Ruscone T, di Terlizzi M, Schafers KP, Luscher TF, Camici PG. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. *Circulation* 2000;**102**:1233-8.
13. Raitakari OT, Adams MR, McCredie RJ, Griffiths KA, Stocker R, Celermajer DS. Oral vitamin C and endothelial function in smokers: short-term improvement, but no sustained beneficial effect. *J Am Coll Cardiol* 2000;**35**:1616-21.
14. Dominici S, Valentini M, Maellaro E *et al*. Redox modulation of cell surface protein thiols in U937 lymphoma cells: the role of γ -glutamyl transpeptidase-dependent H_2O_2 production and S-thiolation. *Free Radic Biol Med* 1999;**27**:623-35.
15. Meacher EA, Barry OP, Burke A *et al*. Alcohol-induced generation of lipid peroxidation products in humans. *J Clin Invest* 1999;**104**:805-13.
16. Zhu J, Katz RJ, Qiyumi AA *et al*. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels: suggestion of pathogen-triggered autoimmunity in early atherosclerosis. *Circulation* 2004;**109**:36-41.

Heart failure 2007: Solutions to difficult problems

One-day meeting for health care professionals

March 14, 2007

Royal College of Physicians, Regent's Park, London

Programme themes:-

- Heart failure in the UK in 2007
- UK and European guidelines
- Healthcare Commission audit data
- Co-morbidity in heart failure
- Critical interface issues
- Networking: the way forward?

There will also be Q/A and discussion sessions

Speakers:-

Professor John McMurray, Glasgow	Jane Butler, London
Professor Martin Cowie, London	Dr Suzanna Hardman, London
Cate Quinn, Healthcare Commission	Dr Theresa McDonagh, London
Dr Jackie Taylor, Glasgow	Maria O'Brien, London Cardiac Network

Chair:

Professor Martin Cowie

CPD accreditation applied for
Supported by an unrestricted educational
grant from Takeda UK



For further information or to book a place at the meeting contact:
www.logoscommunications.co.uk or ring 020 7351 8856
Early booking advisable



Scottish Heart and Arterial Disease Risk Prevention Spring Scientific Meeting

WOMEN AND HEART DISEASE

24th – 25th May 2007

Hilton Dunkeld House Hotel, Perthshire

For further information, contact:
Dr S R McEwan;
Tel: 01382 660111, ext 33124;
email: s.r.mcewan@dundee.ac.uk